XML 23 R8.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2021
Statement of Cash Flows [Abstract]      
Net income $ 105,813 $ 242,870 $ 396,870
Adjustments to reconcile net (loss) income to net cash provided by operating activities:      
Depreciation, depletion, and amortization 552,897 553,104 [1] 219,237
Deferred income taxes (185,913) (106,620) 4,240
Share-based compensation 38,951 57,660 25,966
Loss on the disposal of property, plant, equipment, and intangibles, net 22,193 15,117 (1,982)
Loss (Gain) on Disposition of Business [2] (67) (874) 2,030
Fair value adjustment related to convertible debt liability 0 27,806 0
Amortization of inventory fair value adjustments 7,363 66,663 0
Goodwill, Impairment Loss [3] 490,565 0 0
Other items (24,832) (21,639) 24,273
Changes in operating assets and liabilities:      
Accounts receivable, net (133,304) (51,969) 12,076
Inventories, net (123,921) (102,922) 3,769
Other current assets (24,086) 7,126 458
Accounts payable 53,342 14,887 (7,213)
Accruals and other, net (22,054) (16,398) 9,916
Net cash provided by operating activities 756,947 684,811 689,640
Investing activities:      
Purchases of property, plant, equipment, and intangibles, net (361,969) (287,563) (239,262)
Proceeds from the sale of property, plant, equipment, and intangibles 14,587 1,741 569
Proceeds from Divestiture of Businesses 6,624 169,712 518
Payments to Acquire Investments 0 0 (4,400)
Investments in businesses, net of cash acquired (42,572) (550,449) (909,192)
Payments for (Proceeds from) Other Investing Activities 0 0 (2,392)
Net cash used in investing activities (383,330) (666,559) (1,154,159)
Financing activities:      
Proceeds from Issuance of Senior Long-term Debt 0 1,350,000 0
Proceeds from Issuance of Debt 0 650,000 550,000
Repayments of Secured Debt (156,875) (345,000) 0
Repayments of Long-term Debt (91,000) (721,284) (35,000)
Repayments of Convertible Debt 0 (371,361) 0
Proceeds Under Credit Facility, net 241,657 (190,174) (30,461)
Amortization of Financing Costs 0 (17,472) (12,846)
Payments of Merger Related Costs, Financing Activities (1,471) (32,679) (2,395)
Repurchases of ordinary shares (308,565) (55,777) (14,646)
Cash dividends paid to common shareholders (183,498) (163,169) (133,837)
Payments to Noncontrolling Interests (794) (997) (4,179)
Proceeds from Noncontrolling Interests 0 3,672 2,258
Proceeds from (Payments for) Other Financing Activities 1,828 10,071 26,726
Net cash (used in) provided by financing activities (498,718) 115,830 345,620
Effect of exchange rate changes on cash and cash equivalents (14,862) (6,293) 19,849
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (139,963) 127,789 (99,050)
Cash and cash equivalents at beginning of period 348,320 220,531 319,581
Cash and cash equivalents at end of period $ 208,357 $ 348,320 $ 220,531
[1] Fiscal 2022 totals include approximately $229,052, $35,531 and $113,099 for Healthcare and Life Sciences, Applied Sterilization Technologies, and Dental, respectively, of amortization of acquired intangible assets and amortization of property "step-up" to fair value. For more information regarding our recent acquisitions and divestitures see Note 2 titled, "Business Acquisitions and Divestitures."
[2] For more information regarding our recent acquisitions and divestitures, refer to Note 2 titled, "Business Acquisitions and Divestitures."
[3] For more information regarding our goodwill impairment loss, refer to Note 3 titled, "Goodwill and Intangible Assets."